GlassScriptPhysician profile
Rose Lindsay
NPI 1497180624
$1,693.19
in general payments reported to CMS, 2019-2025
11 companies · $804 in 2025
The $804 reported for 2025 was more than what 76% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $248 · 2023: $356 · 2024: $286 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,412 · Education: $32.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,412.45 |
| Education | $32.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $413.61 | 2022-2025 | Invega Trinza, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $311.37 | 2024-2025 | Caplyta |
| Alkermes, INC. | $246.59 | 2022-2023 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $158.59 | 2024-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $147.77 | 2023-2025 | Austedo Xr, Uzedy |
| Abbvie INC. | $136.97 | 2022-2025 | |
| Lundbeck LLC | $85.56 | 2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $83.65 | 2022 | |
| Axsome Therapeutics, INC. | $63.72 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $27.27 | 2024 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $18.09 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Lindsay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.